Form 8-K - Current report:
SEC Accession No. 0001193125-25-062031
Filing Date
2025-03-25
Accepted
2025-03-25 09:05:15
Documents
14
Period of Report
2025-03-21
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d908716d8k.htm   iXBRL 8-K 26917
  Complete submission text file 0001193125-25-062031.txt   188293

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nuvb-20250321.xsd EX-101.SCH 4248
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nuvb-20250321_def.xml EX-101.DEF 13886
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nuvb-20250321_lab.xml EX-101.LAB 23297
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nuvb-20250321_pre.xml EX-101.PRE 14854
16 EXTRACTED XBRL INSTANCE DOCUMENT d908716d8k_htm.xml XML 6202
Mailing Address 357 TEHAMA STREET, FLOOR 3 SAN FRANCISCO CA 94103
Business Address 357 TEHAMA STREET, FLOOR 3 SAN FRANCISCO CA 94103 (415) 754-3517
Nuvation Bio Inc. (Filer) CIK: 0001811063 (see all company filings)

EIN.: 850862255 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39351 | Film No.: 25766096
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)